Archives for July 29th, 2018
WuXi’s API production site in china passes USFDA’s inspection
Custom Synthesis, WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the Food...
Neurodegeneration may be tied to drainage issues in the brain
Custom Synthesis, PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system, based on the...
Positive data supports product opportunities for XF-73 in dermal infection indications
Custom Synthesis, Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for...